Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations

Heart Rhythm

Volumn 5, Issue 7, 2008, Pages 1019-1026

  Sicouri, Serge ^a   Glass, Aaron ^a   Belardinelli, Luiz ^b   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^b CV THERAPEUTICS INC   (United States)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Electrophysiology; Pharmacology; Sodium channel blocker

Indexed keywords

ACETYLCHOLINE; CALCIUM ION; ISOPRENALINE; RANOLAZINE; SODIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG EXPOSURE; EXCITABILITY; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; MEMBRANE POTENTIAL; MICROELECTRODE; NONHUMAN; PRIORITY JOURNAL; PULMONARY VEIN; REFRACTORY PERIOD;

ACETANILIDES; ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DOGS; HEART CONDUCTION SYSTEM; PIPERAZINES; PULMONARY VEINS;

EID: 46349111138     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2008.03.018     Document Type: Article

References (31)

1. Fuster V. Atrial fibrillation: an epidemiologic, scientific and clinical challenge. Nat Clin Pract Cardiovasc Med 2 (2005) 225
2. Haissaguerre M., Jais P., Shah D.C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339 (1998) 659-666
3. Burashnikov A., and Antzelevitch C. Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. PACE 29 (2006) 290-295
4. Patterson E., Po S.S., Scherlag B.J., et al. Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm 2 (2005) 624-631
5. Patterson E., Lazzara R., Szabo B., et al. Sodium-calcium exchange initiated by the Ca2+ transient: an arrhythmia trigger within pulmonary veins. J Am Coll Cardiol 47 (2006) 1196-1206
6. Wongcharoen W., Chen Y.C., Chen Y.J., et al. Aging increases pulmonary veins arrhythmogenesis and susceptibility to calcium regulation agents. Heart Rhythm 4 (2007) 1338-1349
7. Lo L.W., Chen Y.C., Chen Y.J., et al. Calmodulin kinase II inhibition prevents arrhythmic activity induced by alpha and beta adrenergic agonists in rabbit pulmonary veins. Eur J Pharmacol 571 (2007) 197-208
8. Antzelevitch C., Belardinelli L., Zygmunt A.C., et al. Electrophysiologic effects of ranolazine: a novel anti-anginal agent with antiarrhythmic properties. Circulation 110 (2004) 904-910
9. Antzelevitch C., Belardinelli L., Wu L., et al. Electrophysiologic properties and antiarrhythmic actions of a novel anti-anginal agent. J Cardiovasc Pharmacol Ther 9 Suppl 1 (2004) S65-S83
10. Burashnikov A., Di Diego J.M., Zygmunt A.C., et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 116 (2007) 1449-1457
11. Scirica B.M. Ranolazine in patients with coronary artery disease. Expert Opin Pharmacother 8 (2007) 2149-2157
12. Scirica B.M., Morrow D.A., Hod H., et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non ST-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 116 (2007) 1647-1652
13. Haissaguerre M., Jais P., Shah D.C., et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 101 (2000) 1409-1417
14. Nattel S., Allessie M.A., and Haissaguerre M. Spotlight on atrial fibrillation-the 'complete arrhythmia'. Cardiovasc Res 54 (2002) 197-203
15. Nattel S. Combined parasympathetic-sympathetic nerve discharge and pulmonary vein afterdepolarizations: a new unifying concept with basic and clinical relevance. Heart Rhythm 2 (2005) 632-633
16. Pappone C., Santinelli V., Manguso F., et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation 109 (2004) 327-334
17. Chen Y.J., Chen S.A., Chang M.S., et al. Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation. Cardiovasc Res 48 (2000) 265-273
18. Chen Y.J., and Chen S.A. Electrophysiology of pulmonary veins. J Cardiovasc Electrophysiol 17 (2006) 220-224
19. Burashnikov A., and Antzelevitch C. Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation 107 (2003) 2355-2360
20. Undrovinas A.I., Belardinelli L., Undrovinas N.A., et al. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 17 (2006) S161-S177
21. Kirchhof P.F., Fabritz C.L., and Franz M.R. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects. Circulation 97 (1998) 2567-2574
22. Costard-Jackle A., and Franz M.R. Frequency-dependent antiarrhythmic drug effects on postrepolarization refractoriness and ventricular conduction time in canine ventricular myocardium in vivo. J Pharmacol Exp Ther 251 (1989) 39-46
23. Lee R.J., Liem L.B., Cohen T.J., et al. Relation between repolarization and refractoriness in the human ventricle: cycle length dependence and effect of procainamide. J Am Coll Cardiol 19 (1992) 614-618
24. Golod D.A., Kumar R., and Joyner R.W. Determinants of action potential initiation in isolated rabbit atrial and ventricular myocytes. Am J Physiol 274 (1998) H1902-H1913
25. Belardinelli L., Shryock J.C., and Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 92 Suppl 4 (2006) iv6-iv14
26. Song Y., Shryock J., Wagner S., et al. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther 318 (2006) 214-222
27. CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 (1989) 406-412
28. Antzelevitch C., Shimizu W., Yan G.X., et al. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 10 (1999) 1124-1152
29. Nattel S., Kneller J., Zou R., et al. Mechanisms of termination of atrial fibrillation by class I antiarrhythmic drugs: evidence from clinical, experimental, and mathematical modeling studies. J Cardiovasc Electrophysiol 14 (2003) S133-S139
30. Chaitman B.R. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 113 (2006) 2462-2472
31. Sicouri S., Timothy K.W., Zygmunt A.C., et al. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm 4 (2007) 638-647